SequelSEC

Decoy Therapeutics Inc. DCOY

Pharmaceutical Preparations · CIK 0001615219 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-03-31
Operating income
-$31.14M
Fiscal year ended 2023-03-31
Free cash flow
Unavailable
Fiscal year ended 2023-03-31

Valuation, from the filing

Public float$1.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th

Decoy Therapeutics Inc. (DCOY) reported revenue of $0 and net income of -$30.84M for the fiscal year ended 2023-03-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Decoy Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Decoy Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-03-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$31.14M
Net income-$30.84M
Research & development$15.12M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$7.16M
Selling & marketingUnavailable

Balance

Decoy Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-03-31
Cash & equivalents$9.27M
Total assets$10.06M
Current assets$9.94M
Total liabilities$4.50M
Current liabilitiesUnavailable
Total equity incl. NCI$5.56M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.51M

Cash flow

Decoy Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-03-31
Operating cash flow-$17.24M
Capital expendituresUnavailable
Investing cash flow$0
Financing cash flow$2.32M
Net change in cash-$14.92M
Stock-based compensation$686.24K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$3.55K

Derived

Decoy Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-03-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratioUnavailable
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DCOY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.